The use of stem cells for the repair of cardiac tissue in ischemic heart disease

Expert Review of Medical Devices

Volumn 8, Issue 2, 2011, Pages 209-225

  Brenner, Christoph ^a   Franz, Wolfgang M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

homing; ischemic heart disease; myocardial infarction; paracrine effects; stem cell therapy; tissue engineering

Indexed keywords

HOMING; ISCHEMIC HEART DISEASE; MYOCARDIAL INFARCTION; PARACRINE; STEM CELL THERAPY;

CARDIOLOGY; CELL CULTURE; DISEASE CONTROL; HEART; TISSUE; TISSUE ENGINEERING;

STEM CELLS;

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACTIVIN A; ASCORBIC ACID; BONE MORPHOGENETIC PROTEIN 4; BUTYRIC ACID; DICKKOPF 1 PROTEIN; ENDOTHELIN; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; HYALURONIC ACID; NOGGIN; OXYTOCIN; PROSTACYCLIN; RETINOIC ACID; SCATTER FACTOR; SITAGLIPTIN; VASCULOTROPIN;

ACUTE HEART INFARCTION; ADULT STEM CELL; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL HOMING; CELL ISOLATION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEMATOPOIETIC STEM CELL; HUMAN; ISCHEMIC HEART DISEASE; MAGNETIC FIELD; MYOBLAST; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; REVIEW; STEM CELL EXPANSION; STEM CELL ISOLATION; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING;

ADULT STEM CELLS; BONE MARROW CELLS; CELL LINE; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION; STEM CELLS; TISSUE ENGINEERING; WOUND HEALING;

EID: 79952600042     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.10.78     Document Type: Review

References (116)

1. Tendera M. How much does Europe invest in the treatment of cardiovascular diseases? Eur. Heart J. 27(13), 1521-1522 (2006). (Pubitemid 43954908)
2. Conley BJ, Young JC, Trounson AO, Mollard R. Derivation, propagation and differentiation of human embryonic stem cells. Int. J. Biochem. Cell Biol. 36(4), 555-567 (2004). (Pubitemid 38316815)
3. Mummery C, Ward D, van den Brink CE et al. Cardiomyocyte differentiation of mouse and human embryonic stem cells. J. Anat. 200(Pt 3), 233-242 (2002). (Pubitemid 34467315)
4. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5), 861-872 (2007). (Pubitemid 350138099)
5. Guan K, Nayernia K, Maier LS et al. Pluripotency of spermatogonial stem cells from adult mouse testis. Nature 440(7088), 1199-1203 (2006).
6. Shao H, Wei Z, Wang L et al. Generation and characterization of mouse parthenogenetic embryonic stem cells containing genomes from non-growing and fully grown oocytes. Cell Biol. Int. 31(11), 1336-1344 (2007). (Pubitemid 47361870)
7. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458(7239), 771-775 (2009).
8. Srivastava D, Ivey KN. Potential of stem-cell-based therapies for heart disease. Nature 441(7097), 1097-1099 (2006). (Pubitemid 43990723)
9. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663-676 (2006) (Pubitemid 44233629)
10. Kitajima S, Takagi A, Inoue T, Saga Y. MesP1 and MesP2 are essential for the development of cardiac mesoderm. Development 127(15), 3215-3226 (2000). (Pubitemid 30649534)
11. Saga Y, Kitajima S, Miyagawa-Tomita S. Mesp1 expression is the earliest sign of cardiovascular development. Trends Cardiovasc. Med. 10(8), 345-352 (2000). (Pubitemid 32448044)
12. David R, Brenner C, Stieber J et al. MesP1 drives vertebrate cardiovascular differentiation through Dkk-1-mediated blockade of Wnt-signalling. Nat. Cell Biol. 10(3), 338-345 (2008). (Pubitemid 351331021)
13. David R, Stieber J, Fischer E et al. Forward programming of pluripotent stem cells towards distinct cardiovascular cell types. Cardiovasc. Res. 84(2), 263-272 (2009).
14. David R, Theiss H, Franz WM. Connexin 40 promoter-based enrichment of embryonic stem cell-derived cardiovascular progenitor cells. Cells Tissues Organs 188(1-2), 62-69 (2008). (Pubitemid 351962230)
15. Müller M, Fleischmann BK, Selbert S et al. Selection of ventricular-like cardiomyocytes from ES cells in vitro. FASEB J. 14(15), 2540-2548. (2000).
16. Zweigerdt R, Burg M, Willbold E, Abts H, Ruediger M. Generation of confluent cardiomyocyte monolayers derived from embryonic stem cells in suspension: a cell source for new therapies and screening strategies. Cytotherapy 5(5), 399-413 (2003). (Pubitemid 37369027)
17. Xu XQ, Graichen R, Soo SY et al. Chemically defined medium supporting cardiomyocyte differentiation of human embryonic stem cells. Differentiation 76(9), 958-970 (2008).
18. Lee MS, Makkar RR. Stem-cell transplantation in myocardial infarction: a status report. Ann. Intern. Med. 140(9), 729-737 (2004).
19. Cooke MJ, Stojkovic M, Przyborski SA. Growth of teratomas derived from human pluripotent stem cells is influenced by the graft site. Stem Cells Dev. 15(2), 254-259 (2006). (Pubitemid 43726503)
20. Xue T, Cho HC, Akar FG et al. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. Circulation 111(1), 11-20 (2005). (Pubitemid 40070838)
21. Grepin C, Nemer G, Nemer M. Enhanced cardiogenesis in embryonic stem cells overexpressing the GATA-4 transcription factor. Development 124(12), 2387-2395 (1997). (Pubitemid 27309738)
22. Singh AM, Li FQ, Hamazaki T, Kasahara H, Takemaru KI, Terada N. Chibby, an antagonist of the Wnt/b-catenin pathway, facilitates cardiomyocyte differentiation of murine embryonic stem cells. Circulation 115(5), 617-626 (2007). (Pubitemid 46226172)
23. David R, Groebner M, Franz WM. Magnetic cell sorting purification of differentiated embryonic stem cells stably expressing truncated human CD4 as surface marker. Stem Cells 23(4), 477-482 (2005). (Pubitemid 40478486)
24. Gassanov N, Er F, Zagidullin N, Hoppe UC. Endothelin induces differentiation of ANP-EGFP expressing embryonic stem cells towards a pacemaker phenotype. FASEB J. 18(14), 1710-1712 (2004). (Pubitemid 39561659)
25. Zandstra PW, Bauwens C, Yin T et al. Scalable production of embryonic stem cell-derived cardiomyocytes. Tissue Eng. 9(4), 767-778 (2003). (Pubitemid 37048117)
26. Okita K, Yamanaka S. Induction of pluripotency by defined factors. Exp. Cell Res. 316(16), 2565-2570 (2010).
27. Zimmermann WH, Schneiderbanger K, Schubert P et al. Tissue engineering of a differentiated cardiac muscle construct. Circ. Res. 90(2), 223-230 (2002). (Pubitemid 34627092)
28. Radisic M, Marsano A, Maidhof R, Wang Y, Vunjak-Novakovic G. Cardiac tissue engineering using perfusion bioreactor systems. Nat. Protoc. 3(4), 719-738 (2008). (Pubitemid 351516766)
29. Zhao YS, Wang CY, Li DX et al. Construction of a unidirectionally beating 3-dimensional cardiac muscle construct. J. Heart Lung Transplant. 24(8), 1091-1097 (2005).
30. Tuzlakoglu K, Reis RL. Biodegradable polymeric fiber structures in tissue engineering. Tissue Eng. Part B Rev. 15(1), 17-27 (2009).
31. Zakharova L, Mastroeni D, Mutlu N et al. Transplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function. Cardiovasc. Res. 87(1), 40-49 (2010).
32. Wu KH, Mo XM, Liu YL. Cell sheet engineering for the injured heart. Med. Hypotheses 71(5), 700-702 (2008).
33. Zimmermann WH, Melnychenko I, Wasmeier G et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat. Med. 12(4), 452-458 (2006).
34. Masuda S, Shimizu T, Yamato M, Okano T. Cell sheet engineering for heart tissue repair. Adv. Drug Deliv. Rev. 60(2), 277-285 (2008). (Pubitemid 350236404)
35. Ott HC, Matthiesen TS, Goh SK et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat. Med. 14(2), 213-221 (2008). (Pubitemid 351214548)
36. Deindl E, Zaruba MM, Brunner S et al. G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J. 20(7), 956-958 (2006).
37. Ince H, Petzsch M, Kleine HD et al. Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) trial. Circulation 112(9 Suppl.), I73-80 (2005). (Pubitemid 41266656)
38. Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P. Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann. NY Acad. Sci. 938, 221-229 (2001).
39. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature 410(6829), 701-705 (2001). (Pubitemid 32290358)
40. Schächinger V, Erbs S, Elsasser A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355(12), 1210-1221 (2006). (Pubitemid 44427445)
41. Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364(9429), 141-148 (2004). (Pubitemid 38891685)
42. Murry CE, Soonpaa MH, Reinecke H et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428(6983), 664-668 (2004). (Pubitemid 38524810)
43. Nygren JM, Jovinge S, Breitbach M et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat. Med. 10(5), 494-501 (2004). (Pubitemid 38667908)
44. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428(6983), 668-673 (2004). (Pubitemid 38524811)
45. Zaruba MM, Huber BC, Brunner S et al. Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival. Cardiovasc. Res. 77(4), 722-731 (2008). (Pubitemid 351301860)
46. Zaruba MM, Theiss HD, Vallaster M et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 4(4), 313-323 (2009).
47. Henning RJ, Aufman J, Shariff M et al. Human umbilical cord blood mononuclear cells decrease fibrosis and increase cardiac function in cardiomyopathy. Regen. Med. 5(1), 45-54 (2010).
48. Sodian R, Schaefermeier P, Abegg-Zips S et al. Use of human umbilical cord blood-derived progenitor cells for tissue-engineered heart valves. Ann. Thorac. Surg. 89(3), 819-828 (2010).
49. Ince H, Petzsch M, Rehders TC, Chatterjee T, Nienaber CA. Transcatheter transplantation of autologous skeletal myoblasts in postinfarction patients with severe left ventricular dysfunction. J. Endovasc. Ther. 11(6), 695-704 (2004). (Pubitemid 40110747)
50. Smits PC, van Geuns RJ, Poldermans D et al. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J. Am. Coll. Cardiol. 42(12), 2063-2069 (2003). (Pubitemid 37549885)
51. Siminiak T, Fiszer D, Jerzykowska O et al. Percutaneous trans-coronary-venous transplantation of autologous skeletal myoblasts in the treatment of post-infarction myocardial contractility impairment: the POZNAN trial. Eur. Heart J. 26(12), 1188-1195 (2005). (Pubitemid 40863125)
52. Herreros J, Prosper F, Perez A et al. Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non-acute myocardial infarction. Eur. Heart J. 24(22), 2012-2020 (2003). (Pubitemid 37420448)
53. Menasche P, Hagege AA, Vilquin JT et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J. Am. Coll. Cardiol. 41(7), 1078-1083 (2003). (Pubitemid 36384891)
54. Siminiak T, Kalawski R, Fiszer D et al. Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: Phase I clinical study with 12 months of follow-up. Am. Heart J. 148(3), 531-537 (2004). (Pubitemid 39265130)
55. Menasche P, Alfieri O, Janssens S et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 117(9), 1189-1200 (2008). (Pubitemid 351552018)
56. Pagani FD, DerSimonian H, Zawadzka A et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J. Am. Coll. Cardiol. 41(5), 879-888 (2003) (Pubitemid 36308400)
57. Formigli L, Zecchi-Orlandini S, Meacci E, Bani D. Skeletal myoblasts for heart regeneration and repair: state of the art and perspectives on the mechanisms for functional cardiac benefits. Curr. Pharm. Des. 16(8), 915-928 (2010).
58. Chamuleau SA, Vrijsen KR, Rokosh DG, Tang XL, Piek JJ, Bolli R. Cell therapy for ischaemic heart disease: focus on the role of resident cardiac stem cells. Neth. Heart J. 17(5), 199-207 (2009).
59. Johnston PV, Sasano T, Mills K et al. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation 120(12), 1075-1083 (2009).
60. Smith RR, Barile L, Cho HC et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 115(7), 896-908 (2007). (Pubitemid 46294730)
61. Davis DR, Zhang Y, Smith RR et al. Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue. PLoS One 4(9), e7195 (2009).
62. Chimenti I, Smith RR, Li TS et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ. Res. 106(5), 971-980 (2010).
63. Tang XL, Rokosh G, Sanganalmath SK et al. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation 121(2), 293-305 (2010).
64. Meyer GP, Wollert KC, Lotz J et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur. Heart J. 30(24), 2978-2984 (2009).
65. Meyer GP, Wollert KC, Lotz J et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (Bone Marrow Transfer to Enhance ST-elevation Infarct Regeneration) trial. Circulation 113(10), 1287-1294 (2006). (Pubitemid 43739450)
66. Dill T, Schächinger V, Rolf A et al. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells and Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy. Am. Heart J. 157(3), 541-547 (2009).
67. Chen SL, Fang WW, Ye F et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am. J. Cardiol. 94(1), 92-95 (2004). (Pubitemid 38813459)
68. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur. Heart J. 28(6), 766-772 (2007). (Pubitemid 46439231)
69. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur. Heart J. 29(15), 1807-1818 (2008).
70. Thomas J, Liu F, Link DC. Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor. Curr. Opin. Hematol. 9(3), 183-189 (2002). (Pubitemid 34275963)
71. Engelmann MG, Theiss HD, Hennig-Theiss C et al. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony- Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J. Am. Coll. Cardiol. 48(8), 1712-1721 (2006). (Pubitemid 44528196)
72. Ripa RS, Jorgensen E, Wang Y et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled Stem Cells in Myocardial Infarction (STEMMI) trial. Circulation 113(16), 1983-1992 (2006).
73. Zohlnhofer D, Ott I, Mehilli J et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 295(9), 1003-1010 (2006).
74. Zohlnhofer D, Dibra A, Koppara T et al. Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. J. Am. Coll. Cardiol. 51(15), 1429-1437 (2008). (Pubitemid 351470028)
75. Kim HK, De La Luz Sierra M, Williams CK, Gulino AV, Tosato G. G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood 108(3), 812-820 (2006). (Pubitemid 44154612)
76. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J. Clin. Invest. 111(2), 187-196 (2003). (Pubitemid 36105917)
77. Petit I, Szyper-Kravitz M, Nagler A et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat. Immunol. 3(7), 687-694 (2002). (Pubitemid 34752479)
78. Stein A, Zohlnhofer D, Pogatsa-Murray G et al. Expression of CXCR4, VLA-1, LFA-3 and transducer of ERB in G-CSF-mobilised progenitor cells in acute myocardial infarction. Thromb. Haemost. 103(3), 638-643 (2010).
79. Brunner S, Winogradow J, Huber BC et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/ SDF-1 axis. FASEB J. 23(2), 351-361 (2009).
80. Theiss HD, Brenner C, Engelmann MG et al. Safety and efficacy of Sitagliptin plus Granulocyte-Colony-Stimulating Factor in Patients Suffering from Acute Myocardial Infarction (SITAGRAMI-trial) - rationale, design and first interim analysis. Int. J. Cardiol. 145(2), 282-284 (2010).
81. Korf-Klingebiel M, Kempf T, Sauer T et al. Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. Eur. Heart J. 29(23), 2851-2858 (2008).
82. Fazel S, Cimini M, Chen L et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J. Clin. Invest. 116(7), 1865-1877 (2006). (Pubitemid 44033311)
83. Saxena A, Fish JE, White MD et al. Stromal cell-derived factor-1a is cardioprotective after myocardial infarction. Circulation 117(17), 2224-2231 (2008).
84. Srivastava D, Saxena A, Michael Dimaio J, Bock-Marquette I. Thymosin b4 is cardioprotective after myocardial infarction. Ann. NY Acad. Sci. 1112, 161-170 (2007).
85. Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li PF. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc. Natl Acad. Sci. USA 106(29), 12103-12108 (2009).
86. Liu N, Bezprozvannaya S, Williams AH et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 22(23), 3242-3254 (2008).
87. Thum T, Gross C, Fiedler J et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456(7224), 980-984 (2008).
88. van Rooij E, Sutherland LB, Liu N et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl Acad. Sci. USA 103(48), 18255-18260 (2006). (Pubitemid 44871645)
89. Kattman SJ, Huber TL, Keller GM. Multipotent flk-1+ cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. Dev. Cell 11(5), 723-732 (2006). (Pubitemid 44644969)
90. Van Hoof D, Dormeyer W, Braam SR et al. Identification of cell surface proteins for antibody-based selection of human embryonic stem cell-derived cardiomyocytes. J. Proteome Res. 9(3), 1610-1618 (2010).
91. Wobus AM, Kaomei G, Shan J et al. Retinoic acid accelerates embryonic stem cell-derived cardiac differentiation and enhances development of ventricular cardiomyocytes. J. Mol. Cell Cardiol. 29(6), 1525-1539. (1997). (Pubitemid 27270224)
92. Paquin J, Danalache BA, Jankowski M, McCann SM, Gutkowska J. Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes. Proc. Natl Acad. Sci. USA 99(14), 9550-9555 (2002). (Pubitemid 34764650)
93. Takahashi T, Lord B, Schulze PC et al. Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. Circulation 107(14), 1912-1916 (2003). (Pubitemid 36444134)
94. Ventura C, Maioli M, Asara Y et al. Butyric and retinoic mixed ester of hyaluronan. A novel differentiating glycoconjugate affording a high throughput of cardiogenesis in embryonic stem cells. J. Biol. Chem. 279(22), 23574-23579 (2004). (Pubitemid 38685671)
95. Ventura C, Maioli M, Asara Y et al. Turning on stem cell cardiogenesis with extremely low frequency magnetic fields. FASEB J. 19(1), 155-157 (2005). (Pubitemid 40069950)
96. Yuasa S, Itabashi Y, Koshimizu U et al. Transient inhibition of BMP signaling by Noggin induces cardiomyocyte differentiation of mouse embryonic stem cells. Nat. Biotechnol. 23(5), 607-611 (2005). (Pubitemid 41724900)
97. Roggia C, Ukena C, Bohm M, Kilter H. Hepatocyte growth factor (HGF) enhances cardiac commitment of differentiating embryonic stem cells by activating PI3 kinase. Exp. Cell Res. 313(5), 921-930 (2006).
98. Mummery CL, Ward D, Passier R. Differentiation of human embryonic stem cells to cardiomyocytes by coculture with endoderm in serum-free medium. Curr. Protoc. Stem. Cell Biol. Chapter 1, Unit 1F.2 (2007).
99. Graichen R, Xu X, Braam SR et al. Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK. Differentiation 76(4), 357-370 (2008). (Pubitemid 351522761)
100. Yang L, Soonpaa MH, Adler ED et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 453(7194), 524-528 (2008). (Pubitemid 351733312)
101. Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367(9505), 113-121 (2006). (Pubitemid 43077127)
102. Lunde K, Solheim S, Aakhus S et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med. 355(12), 1199-1209 (2006). (Pubitemid 44427444)
103. Tendera M, Wojakowski W, Ruzyllo W et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) trial. Eur. Heart J. 30(11), 1313-1321 (2009).
104. Gyongyosi M, Lang I, Dettke M et al. Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. Nat. Clin. Pract. Cardiovasc. Med. 6(1), 70-81 (2009).
105. Surder D, Schwitter J, Moccetti T et al. Cell-based therapy for myocardial repair in patients with acute myocardial infarction: rationale and study design of the Swiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction (SWISS-AMI). Am. Heart J. 160(1), 58-64 (2010).
106. Zhao Y, Ransom JF, Li A et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129(2), 303-317 (2007). (Pubitemid 46574975)
107. Maurer B, Stanczyk J, Jungel A et al. miR-29 is a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 62(6), 1733-1743 (2010).
108. van Rooij E, Sutherland LB, Thatcher JE et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl Acad. Sci. USA 105(35), 13027-13032 (2008).
109. Wang S, Aurora AB, Johnson BA et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 15(2), 261-271 (2008).
110. Wang S, Olson EN. AngiomiRs - key regulators of angiogenesis. Curr. Opin. Genet. Dev. 19(3), 205-211 (2009).
111. Li Q, Lin X, Yang X, Chang J. NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repression. Am. J. Physiol. Heart Circ. Physiol. 298(5), H1340-H1347 (2010).
112. Gonsalves CS, Kalra VK. Hypoxia-mediated expression of 5-lipoxygenase-activating protein involves HIF-1a and NF-kB and microRNAs 135a and 199a-5p. J. Immunol. 184(7), 3878-3888 (2010)
113. Rane S, He M, Sayed D et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1a and sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ. Res. 104(7), 879-886 (2009).
114. Callis TE, Pandya K, Seok HY et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. 119(9), 2772-2786 (2009).
115. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316(5824), 575-579 (2007). (Pubitemid 46683138)
116. Ren XP, Wu J, Wang X et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 119(17), 2357-2366 (2009).